UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
|
| |||
(State or Other Jurisdiction | (Commission | (I.R.S. Employer |
(Address of Principal Executive Offices) | (Zip Code) |
| ( |
|
(Registrant’s Telephone Number, Including Area Code) | ||
| N/A |
|
(Former Name or Former Address, if Changed Since | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 28, 2023, the Board of Directors of NeuBase Therapeutics, Inc. (the “Company”) approved an amendment (the “Plan Amendment”) to the NeuBase Therapeutics, Inc. 2019 Stock Incentive Plan (the “2019 Plan”) to change the effectiveness date of the 2019 Plan’s “evergreen” provision, pursuant to which the maximum number of shares of the Company’s common stock that may be issued under the life of the 2019 Plan will automatically increase, from October 1st of each year to January 1st of each year. The Plan Amendment was adopted to align with the Company's recent change of its fiscal year end from September 30th to December 31st, commencing with the fiscal year ending December 31, 2023.
The summary of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan Amendment, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits
Exhibit Number |
| Description | |
10.1 | Amendment No. 1 to NeuBase Therapeutics, Inc. 2019 Stock Incentive Plan. | ||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEUBASE THERAPEUTICS, INC. (Registrant) | ||
Date: July 31, 2023 | By: | /s/ Todd P. Branning |
Todd P. Branning | ||
Chief Financial Officer (Principal Financial and Accounting Officer) | ||